AXL and non-small cell lung carcinoma: Our data demonstrate that MTE is effective in EGFR-TKI resistant HCC827/ER NSCLC cells through co-inhibition of the EGFR downstream pathways and the bypass signaling molecules dictated by Met or Axl.